Diagnostic tech developer Masimo (NSDQ:MASI) and rival Dominion have settled a suit over blood monitoring patents, according to recently released court documents.
The two companies said they reached a settlement deal over a suit brought against Masimo by Dominion claiming it infringed on patents related to noninvasive blood monitoring technology.
The agreement does not include payments from either company, and leaves both sides to pay for their own legal costs, according to court documents.
The settlement deal was signed by US District Judge Beth Freeman on Tuesday.
Earlier this week, Masimo released results from a study exploring home pulse oximetry monitoring’s ability to serve as an initial screening method to determine which children with Down syndrome should be recommended to undergo sleep studies to diagnose obstructive sleep apnea.
